MRK250117C109000
- 0.02
- 0.000.00%
Merck & Co Newsroom
Price Over Earnings Overview: Merck & Co
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $125
Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value
Boeing, NVIDIA Corp. Share Losses Lead Dow's 113-Point Drop
Merck Speeds Up Launch of New Keytruda Version as Patent Expiration Nears -- Barrons.com
BMO Capital Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $105
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150
Merck & Co.'s Accelerated Keytruda Launch and Strategic Updates Bolster Long-term Growth Prospects
Merck Eyeing 2025 Launch for Easier-to-use Keytruda
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
Merck (MRK.US) is expected to launch a simplified version of the cancer drug Keytruda in 2025.
Merck (MRK.US) is expected to launch a more easily manageable version of its best-selling cancer treatment drug Keytruda by the end of this year.
The arrangement for Trump's inauguration ceremony has been announced: it is expected to cost 0.037 million dollars per minute.
① The inauguration activities of the president-elect Trump in the USA have been announced, including an official party, a MAGA rally, and a large fireworks display, with multiple events taking place at Trump's golf course outside Washington, D.C. ② Trump's inaugural committee has raised over $0.17 billion, expected to reach $0.2 billion, spending $0.037 million per minute, far exceeding the record of $8,600 per minute set during Obama's first inauguration.
GSK Acquiring US-Based IDRx for up to $1.15 Billion
Merck & Co To Present At J.P. Morgan Healthcare Conference; Webcast At 7:30 PM ET
UnitedHealth, Caterpillar Share Gains Contribute To Dow's 240-Point Climb
Merck Is Maintained at Outperform by Leerink Partners
Merck & Co Analyst Ratings
Express News | Merck & Co Inc : Leerink Partners Cuts Target Price to $119 From $136
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong Fundamentals